About
Beijing Ribio Pharmaceutical Technology Co., Ltd.
Ribio has extensive technological expertise in the fields of carbohydrate chemistry, nucleoside chemistry, and phosphorus chemistry. To date, the company holds 13 invention patents and has commercialized products including modified ribose, modified nucleosides, nucleoside analogs, phosphoramidite monomers, and various GalNAc delivery carriers—key building blocks for small nucleic acid drugs.
The company’s technical core team consists of experts from prestigious institutions such as Tsinghua University, Peking University, and the University of Zurich, with over a decade of industry experience in R&D and industrialization. Capable of efficiently meeting diverse client needs, Ribio is one of China’s leading companies in the research, development, and production of nucleic acid drug materials.
The R&D center, located in Beijing Daxing Biomedical Industry Base, is equipped with advanced analytical instruments such as MS-LC, HPLC, GC, and KF, and maintains close collaborations with Peking University, Tsinghua University, and the Institute of Chemistry, Chinese Academy of Sciences.
The production base, situated in Mingxi Economic Development Zone, Fujian Province Chemical Park, has a registered capital of 50 million RMB and has invested over 100 million RMB in infrastructure. With complete production facilities, it can accommodate demands ranging from kilogram to hundred-ton scale. The base is ISO-certified and has passed supplier audits by multiple renowned domestic and international pharmaceutical companies.
Since its establishment, RiboBio has been honored with numerous accolades, including:
National High-Tech Enterprise
Fujian Provincial Specialized, Refined, Distinctive, and Innovative SME
Innovative SME
Technology-based SME
Technology Giant SME
"Science China" Doctoral Innovation Station
Adhering to the principle of "credibility first, customer foremost," we sincerely welcome partners to visit, collaborate, and jointly build a brighter future!
Research
Beijing Ribio Pharmaceutical Technology Co., Ltd., founded in 2017 and headquartered at the Beijing Daxing Biomedical Industry Base, is a high-tech enterprise certified by the Beijing Municipal Science & Technology Commission.
The company's R&D center is equipped with advanced analytical instruments, including MS-LC, HPLC, GC, and KF, and maintains close collaborations with leading institutions such as Peking University, Tsinghua University, and the Institute of Chemistry, Chinese Academy of Sciences.
Since its establishment, the center has received multiple project grants from the Beijing Municipal Science & Technology Commission, supporting its innovative research and development efforts.
Team
Beijing Ribio Pharmaceutical Technology Co., Ltd., founded in 2017 and headquartered at the Beijing Daxing Biomedical Industry Base, is a high-tech enterprise certified by the Beijing Municipal Science & Technology Commission.
The company's R&D center is equipped with advanced analytical instruments, including MS-LC, HPLC, GC, and KF, and maintains close collaborations with leading institutions such as Peking University, Tsinghua University, and the Institute of Chemistry, Chinese Academy of Sciences.
Since its establishment, the center has received multiple project grants from the Beijing Municipal Science & Technology Commission, supporting its innovative research and development efforts.
Result
Beijing Ribio Pharmaceutical Technology Co., Ltd., founded in 2017 and headquartered at the Beijing Daxing Biomedical Industry Base, is a high-tech enterprise certified by the Beijing Municipal Science & Technology Commission.
The company's R&D center is equipped with advanced analytical instruments, including MS-LC, HPLC, GC, and KF, and maintains close collaborations with leading institutions such as Peking University, Tsinghua University, and the Institute of Chemistry, Chinese Academy of Sciences.
Since its establishment, the center has received multiple project grants from the Beijing Municipal Science & Technology Commission, supporting its innovative research and development efforts.
